RedHill Biopharma OKs all EGM resolutions

RedHill Biopharma Ltd. reported that at its Extraordinary General Meeting of Shareholders held on March 5, 2026, all resolutions proposed to shareholders were duly approved.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. reported that at its Extraordinary General Meeting of Shareholders held on March 5, 2026, all resolutions proposed to shareholders were duly approved. The company also states that this report is incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements previously filed with the U.S. securities regulator.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RedHill Biopharma (RDHL) shareholders approve at the March 2026 extraordinary meeting?

Shareholders approved all resolutions presented at the March 5, 2026 extraordinary meeting. The specific resolutions are not detailed here, but the filing confirms that every proposal brought to a vote received shareholder approval at that meeting.

What is the purpose of RedHill Biopharma’s March 2026 Form 6-K filing?

The Form 6-K confirms that all resolutions at the March 5, 2026 extraordinary shareholders’ meeting were approved. It also formally incorporates this information into several of RedHill’s existing Form S-8 and Form F-3 registration statements with the U.S. securities regulator.

How does this Form 6-K affect RedHill Biopharma’s existing registration statements?

The report is expressly incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements. This means the information about the March 5, 2026 extraordinary meeting becomes part of those effective registration documents for legal and disclosure purposes.

Which SEC forms does RedHill Biopharma (RDHL) use for its annual reporting?

The document indicates RedHill Biopharma uses Form 20-F for its annual reporting as a foreign private issuer. Form 20-F is the standard annual report format used by non-U.S. companies whose securities trade in U.S. markets.

Who signed RedHill Biopharma’s March 2026 Form 6-K and in what capacity?

The Form 6-K was signed on behalf of RedHill Biopharma Ltd. by Dror Ben-Asher. He signed in his capacity as Chief Executive Officer, confirming the company’s authorization of the report under applicable U.S. securities regulations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 09:00 AM EST Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of March 2026
Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha'arba'a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐

At the Extraordinary General Meeting of Shareholders of RedHill Biopharma Ltd. (the “Company”) held on March 5, 2026, all of the resolutions proposed to the shareholders were duly approved. Below are the proposals adopted:

1. To approve the grant of restricted share units (“RSUs”), each with respect to one American Depository Share (each representing 10,000 ordinary shares, par value NIS 0.01 each) to the non-executive directors of the Company;

2. To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company’s Chief Executive Officer and Chairman of the Board of Directors;

3. To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company’s Chief Commercial Officer, and Director; and

4. To approve an increase in the Company’s authorized share capital.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the "Registrant")
Date: March 5, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer